Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
The future of antibody claiming in the United States is uncertain following the U.S. Supreme Court’s May 2023 ruling in Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), a highly anticipated decision concerning enablement and whether the traditional way to claim antibodies — claiming antibodies by their function — will survive as a valid claiming strategy.
Continue reading by getting
started with a subscription.
By Matthew R. Carey
The possibilities for patenting innovative applications of multimodal models across industries are endless.
By Ed Lanquist, Jr. and Dominic Rota
Just like any new technology, efforts to protect and enforce intellectual property on AI-based technologies are likely to be hampered by a lack of both a unified governing framework and a common understanding of the technology.
By Stan Soocher
A recent New York federal court decision in a dispute between a broker that sublicenses program content and a broadcaster that sublicensed content from the broker considered the interaction of contract language and extra-contractual elements of the parties’ relationship to determine whether a fiduciary relationship existed.
By Rob Maier
A recent order from Chief Judge Colm Connolly in the U.S. District Court for the District of Delaware may serve as a warning for “patent trolls” — the derogatory term used to describe companies whose sole function is to acquire and then assert patents, often in cases that are questionable on the merits — against filing cases in Delaware going forward.